Alan Ezekowitz Buys 15,000 Shares of Septerna, Inc.

Alan Ezekowitz, an insider, bought 15,000 shares of Septerna, Inc. (NasdaqGM: SEPN) on June 26, 2026. This transaction was not part of a planned purchase. The stock traded near $34.75 on Wednesday.

Insider Buying and Selling at Septerna, Inc.

On June 26, 2026, Alan Ezekowitz bought 15,000 shares of Septerna, Inc. This insider transaction was not planned, indicating a direct purchase. Additionally, Bernard Coulie also acquired 15,000 shares on the same day, and Samira Shaikhly, the Chief People Officer, had several transactions on June 29, 2026, including buying 2,178 shares at $6.81.

Other Institutional Activity in Septerna, Inc.

RA Capital Management, L.P. held steady with 6,995,858 shares valued at about $168.1 million. TRV GP V, LLC also maintained its position with 6,215,591 shares worth approximately $149.4 million. Driehaus Capital Management LLC reduced its holdings by 413,898 shares, ending with 4,395,572 shares valued at around $105.6 million, marking an 8.6% decrease. Goldman Sachs Group Inc. increased its stake by 191,298 shares to reach 2,906,427 shares, valued at about $69.8 million, a 7% increase.

Septerna, Inc. Stock Down 12.2%

Shares of Septerna, Inc. traded near $34.75 on Wednesday. The company has a market capitalization of approximately $1.68 billion. Septerna isn't currently profitable, so it doesn't have a meaningful P/E ratio. The stock's 52-week range is between $10.30 and $37.99, with a 50-day moving average of $28.91 and a 200-day moving average of $25.31. The company maintains a current ratio of 4.71 and a quick ratio of 4.63, with a debt-to-equity ratio of 6.10.

Recent Earnings

Septerna, Inc. reported revenue of $72.3 million, reflecting a substantial growth of 120.1%. However, the company posted a net margin of -49.9% and a return on equity of -9.3%. The next earnings report is expected on August 10, 2026.

Analysts Set New Price Targets

On June 8, 2026, Raymond James maintained a buy rating for Septerna, Inc., setting a price target of $53.0. Other firms such as JP Morgan, Truist Securities, and Wells Fargo also maintained buy ratings with targets of $38.0, $35.0, and $48.0, respectively. The consensus among nine analysts is a strong buy, with a mean price target of $45.78.

About Septerna, Inc.

Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small molecule products targeting G protein-coupled receptors (GPCRs). These products aim to treat a range of conditions, including endocrinology, immunology, and metabolic diseases. The company is headquartered in South San Francisco, California, and led by CEO Dr. Jeffrey T. Finer. Septerna collaborates with Novo Nordisk to develop therapies for metabolic diseases.

Bottom Line

Insider buying by Alan Ezekowitz reflects ongoing interest in Septerna, Inc., a company working on innovative healthcare solutions. The stock's performance and analyst ratings suggest positive sentiment. As always, remember that insider transactions are disclosed after the fact and may not indicate future stock performance.